Conservative commentator Charlie Kirk shot and killed at Utah event
Investing.com - H.C. Wainwright has reiterated a Buy rating and $136.00 price target on BioNTech (NASDAQ:BNTX), a $27 billion market cap biotech company, following positive clinical trial results for its cancer treatment. The company maintains strong financial health with a current ratio of 8.61 and minimal debt levels, according to InvestingPro data.
The pivotal Phase 3 trial evaluating trastuzumab pamirtecan (BNT323/DB-1303), a HER2-targeted antibody-drug conjugate, met its primary endpoint of progression-free survival at a pre-specified interim analysis, according to an announcement from BioNTech and its partner Duality Biologics (9606.HK). The news has contributed to BioNTech’s significant 12.46% stock return over the past week. For deeper insights into BioNTech’s financial health and growth prospects, check out the comprehensive Pro Research Report available on InvestingPro.
The trial compared BNT323/DB-1303 against trastuzumab emtansine (T-DM1) in patients with HER2+ unresectable or metastatic breast cancer who had previously received trastuzumab and taxane-based chemotherapy.
H.C. Wainwright views this development as "incrementally positive" for BioNTech and believes it bodes well for the global Phase 3 DYNASTY-Breast02 trial, which is evaluating BNT323 in HR+, HER2-low metastatic breast cancer.
BioNTech also plans to evaluate a combination of BNT323 with its PD-L1 x VEGF inhibitor, BNT327, as part of its expanding oncology portfolio, which H.C. Wainwright believes positions the company as "a leader in the oncology space."
In other recent news, BioNTech has amended its co-development and co-commercialization agreement with Bristol-Myers Squibb for the investigational bispecific antibody BNT327. The revised agreement includes a $1.5 billion upfront payment to BioNTech, along with $2 billion in non-contingent anniversary payments through 2028. Additionally, BioNTech is eligible to receive up to $7.6 billion in development, regulatory, and commercial milestone payments. In another development, BioNTech reported positive results from a Phase 3 trial of its anti-HER2 antibody drug conjugate in breast cancer patients, leading BMO Capital to maintain its Outperform rating on the company. However, H.C. Wainwright lowered its price target for BioNTech to $136 due to increased operating expenses, while maintaining a Buy rating. The company reported a net loss of €1.60 per diluted share for the second quarter of 2025, missing expectations, with revenue significantly below estimates at €339.0 million. These developments highlight BioNTech’s ongoing efforts in advancing its cancer treatment pipeline amidst financial challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.